Occam's Razor Dulled: A Curious Case of Dyspnea in a 70‐Year‐Old

avidity

[1]  T. Egberts,et al.  Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database. , 2021, European Review for Medical and Pharmacological Sciences.

[2]  R. Blankstein,et al.  Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus , 2021, Journal of the American Heart Association.

[3]  S. Seth,et al.  Comparison of 68Ga-DOTANOC PET/CT with cardiac MRI in patients with clinical suspicion of cardiac sarcoidosis , 2021, Annals of Nuclear Medicine.

[4]  B. Borlaug,et al.  Unmasking Hydroxychloroquine Cardiotoxicity in a Patient With Heart Failure and Chronotropic Incompetence , 2021, JACC. Case reports.

[5]  R. Muller.  Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities , 2021, Rheumatology International.

[6]  L. Naldi,et al.  The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. , 2021, Clinical and experimental rheumatology.

[7]  Gene Kim,et al.  Chloroquine- and Hydroxychloroquine–Induced Cardiomyopathy: A Case Report and Brief Literature Review , 2020, American journal of clinical pathology.

[8]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[9]  A. Askanase,et al.  Endomyocardial biopsies in the diagnosis of myocardial involvement in systemic lupus erythematosus , 2020, Lupus.

[10]  P. Elliott,et al.  Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta‐analysis , 2019, ESC heart failure.

[11]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[12]  D. Gladman,et al.  Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered? , 2018, The Journal of Rheumatology.

[13]  M. Maurer,et al.  Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types , 2018, Current opinion in cardiology.

[14]  Kyle S. Conway,et al.  Cardiac Involvement in Sarcoidosis Deaths in Wayne County, Michigan , 2018, Academic forensic pathology.

[15]  D. Gladman,et al.  Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials? , 2018, The Journal of Rheumatology.

[16]  D. Gladman,et al.  Antimalarial-induced cardiomyopathy: a systematic review of the literature , 2018, Lupus.

[17]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[18]  P. Elliott,et al.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.

[19]  Q. Fang,et al.  Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis , 2016, BMC Cardiovascular Disorders.

[20]  A. Cayota,et al.  Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study , 2015, Lupus.

[21]  Robert L. Davis,et al.  A Prospective Study of the Incidence of Myocarditis/Pericarditis and New Onset Cardiac Symptoms following Smallpox and Influenza Vaccination , 2015, PloS one.

[22]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[23]  J. Miner,et al.  Cardiac manifestations of systemic lupus erythematosus. , 2014, Rheumatic diseases clinics of North America.

[24]  Stefan Neubauer,et al.  T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. , 2013, JACC. Cardiovascular imaging.

[25]  A. Fabre,et al.  Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review , 2013, European heart journal. Acute cardiovascular care.

[26]  M. Russo,et al.  Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. , 2012, International journal of cardiology.

[27]  S. Katz,et al.  Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action , 2011, Current opinion in rheumatology.

[28]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[29]  C. Tschöpe,et al.  Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis , 2010, Heart.

[30]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[31]  A. Einstein,et al.  Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. , 2008, Chest.

[32]  N. Düzgün.  Amyloid A amyloidosis and systemic lupus erythematosus , 2007, Expert review of clinical immunology.

[33]  F. Saremi,et al.  Utility of cardiac MRI for diagnosis and post-treatment follow-up of lupus myocarditis , 2007, The International Journal of Cardiovascular Imaging.

[34]  Serguei V. S. Pakhomov,et al.  Systolic and diastolic heart failure in the community. , 2006, JAMA.

[35]  K. Klingel,et al.  Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis , 2006, Circulation.

[36]  M. Nishimura,et al.  Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. , 2005, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[37]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[38]  T. Regan,et al.  Alcoholic cardiomyopathy: is it dose-dependent? , 2002, Congestive heart failure.

[39]  S. Dimauro,et al.  Clinicopathological features of genetically confirmed Danon disease , 2002, Neurology.

[40]  P. Whelton,et al.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. , 2001, Archives of internal medicine.

[41]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[42]  H. Hishida,et al.  Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. , 1999, American heart journal.

[43]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[44]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[45]  A. Mackenzie,et al.  Pharmacologic actions of 4-aminoquinoline compounds. , 1983, The American journal of medicine.

[46]  F. O'grady,et al.  Experimental chloroquine myopathy. , 1966, Journal of neurology, neurosurgery, and psychiatry.

[47]  G. Johnson,et al.  Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium-Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. , 2018, Circulation. Cardiovascular imaging.

[48]  M. Piano.  Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. , 2002, Chest.

[49]  H. Fleming.  Cardiac sarcoidosis. , 1986, Clinics in dermatology.